CVS Health shares have been rebounding after pandemic-era headwinds, and the latest sign of improving fundamentals came with the company’s first-quarter results. According to the company’s reporting, revenue rose year over year to $100.4 billion and adjusted earnings per share increased to $2.57, beating analyst expectations—an outcome investors typically read as momentum returning to the business, particularly in insurance.
Over the past year, CVS Health stock has climbed 48%, but the key question for markets is whether operational improvements in the Medicare Advantage and insurance segment can sustain profit growth as the company adjusts its strategy.
Key takeaways
- Price move: CVS Health shares have gained 48% over the past 12 months.
- Catalyst: The company reported a raise-and-beat first quarter, including year-over-year adjusted EPS growth and an improvement in medical benefit ratio.
- What changed: A lower medical benefit ratio and digitization of prior authorization helped improve insurance profitability.
- Implication: CVS expects further improvement, including increased fiscal-year 2026 EPS guidance, while also planning changes to its Medicare Advantage footprint.
What drove the move
The rebound in CVS Health’s results has been closely tied to its insurance performance. After the pandemic, the company faced slower revenue growth and rising expenses that pressured margins, according to the article’s description of the prior challenges. In particular, CVS struggled with utilization and costs in its health insurance business, with Medicare Advantage proving to be a difficult area.
That uncertainty showed up in guidance revisions in the period after the pandemic, the report said. However, more recent results have suggested the company is stabilizing trends. In the first quarter discussed in the article, CVS reported:
- Revenue: up about 6% year over year to $100.4 billion.
- Adjusted earnings per share: up about 14% year over year to $2.57.
- Guidance: CVS increased its EPS guidance for fiscal year 2026, according to the report.
Two operational factors were highlighted as supporting the improvement. First, CVS’s medical benefit ratio (MBR) fell to 84.6% in the quarter, down 2.7% versus the first quarter of 2025, according to the article. The MBR tracks the share of premium revenue that is spent on members’ healthcare costs; a lower MBR typically implies better underwriting economics and can support earnings.
Second, the company improved insurance efficiency by digitizing the prior authorization process, the article said. By reducing friction in approvals, CVS may be able to better manage utilization patterns and control claims-related costs.
Market reaction: “raise-and-beat” sets a higher bar
CVS’s quarter came in ahead of analyst estimates, described in the article as a “raise-and-beat” outcome. While the piece does not provide the exact market reaction on the specific earnings date, it frames the stock’s broader 12-month increase as consistent with investors rewarding improvements in insurance profitability and forward outlook.
For investors, the key market implication is that the company is not only delivering results but also signaling that its improved performance may continue. Increasing full-year 2026 EPS guidance suggests management sees enough confidence in cost and utilization trends to commit to higher expectations—an important signal in a segment where prior guidance cuts reflected uncertainty.
Bigger picture: Medicare Advantage strategy and long-term positioning
The article notes that CVS has yet to realize the full effect of its initiatives and expects to “double down” on efforts to improve its business. A specific strategic point mentioned is that the company had plans to scale back its Medicare Advantage business this year. While reducing that footprint could weigh on overall revenue, the article says CVS’s goal is to prioritize profitable growth rather than top-line expansion at any cost.
Beyond near-term execution, the report argues that CVS’s diversified healthcare model could provide resilience. It describes the company as spanning primary care operations, insurance, pharmacy services, and related patient services under a single umbrella. The vertical integration, according to the article, can help reduce total expenses by directing patients toward lower-cost options.
Secular demand is also part of the long-term thesis cited in the piece. It points to demographic trends—especially the aging population—as a driver of higher healthcare utilization and spending. In addition, CVS is characterized in the article as an established dividend payer, noting that the company increased its payouts by 56.5% over the past decade and offers a forward dividend yield of 2.6%.
Valuation was presented as another supportive factor. The article states CVS Health is trading at 13.8 times forward earnings versus the healthcare sector’s average of 17.4 times, implying the stock may still be priced below the group even after its strong run.
What to watch next
Investors will likely focus on whether CVS can sustain insurance profitability improvements reflected in the medical benefit ratio and whether its digitization efforts continue to reduce prior authorization friction and manage utilization. The company’s decision to scale back Medicare Advantage while increasing EPS guidance also sets up an execution test: how revenue trends evolve versus margin and earnings progress.
With CVS projecting higher fiscal-year 2026 EPS, the next checkpoints will be subsequent quarterly updates, continued guidance commentary, and ongoing indicators from the insurance book—especially those tied to utilization and claims costs.
